Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment
- Conditions
- Type 2 Diabetes MellitusDyslipidemia
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Institut Investigacio Sanitaria Pere Virgili
- Target Recruit Count
- 30
- Registration Number
- NCT02153879
- Locations
- 🇪🇸
Hospital Universitari Sant Joan, Reus, Tarragona, Spain
Early Aortic Valve Lipoprotein(a) Lowering Trial
- Conditions
- Aortic Stenosis and Lipoprotein(a) Levels
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- George Thanassoulis
- Registration Number
- NCT02109614
- Locations
- 🇨🇦
MUHC - Royal Victoria Hospital, Montreal, Quebec, Canada
🇨🇦MUHC - Montreal General Hospital, Montreal, Quebec, Canada
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
Niacin on Immune Activation : a Proof-of-concept Study
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 16
- Registration Number
- NCT02018965
- Locations
- 🇨🇦
Montreal Chest Institute, Montreal, Quebec, Canada
Assessment Of Vascular Health After Niacin Therapy (AVANT)
- Conditions
- Coronary Artery DiseaseCarotid Artery DiseasePeripheral Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 9
- Registration Number
- NCT02003638
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Short-term Effect of Extended-release Niacin on Endothelial Function.
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 18
- Registration Number
- NCT01942291
- Locations
- 🇧🇷
University of Campinas, Campinas, SP, Brazil
Benefit of Elevation of HDL-C in Women
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT01921010
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Cortria Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01809301
- Locations
- 🇨🇦
Bio Pharma Services Inc. (BPSI), Toronto, Ontario, Canada
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 22
- Registration Number
- NCT01720095
- Locations
- 🇨🇦
NS Early Psychosis Program, Halifax, Nova Scotia, Canada
Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Xavier Pinto Sala
- Target Recruit Count
- 12
- Registration Number
- NCT01450410
- Locations
- 🇪🇸
Unitat Funcional de Risc Vascular. Servei Medicina Interna. Hospital Universitari de Bellvitge., L'Hospitalet de Llobregat, Barcelona, Spain
Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 99
- Registration Number
- NCT01426438
- Locations
- 🇺🇸
University of Colorado Hospital CRS (6101), Aurora, Colorado, United States
🇺🇸NY Univ. HIV/AIDS CRS (401), New York, New York, United States
🇺🇸University of Southern California (1201), Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.